General
Preferred name
MUBRITINIB
Synonyms
TAK 165 ()
TAK-165 ()
Mubritinib (TAK 165) ()
TAK165 ()
P&D ID
PD010822
CAS
366017-09-6
Tags
available
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 1
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mubritinib is a reversible inhibitor of EGFR and HER2. This compound is a Phase I clinical candidate.
(GtoPdb)
DESCRIPTION
Potent and selective ErbB2 inhibitor
(Tocriscreen Plus)
DESCRIPTION
Phospholipase D inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Potent and selective ErbB2 inhibitor
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
20
Molecular Weight
468.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
10
Ring Count
4
Aromatic Ring Count
4
cLogP
6.06
TPSA
65.97
Fraction CSP3
0.24
Chiral centers
0.0
Largest ring
6.0
QED
0.26
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzyme-Linked Receptors
Targets
ERBB2
Pathway
Angiogenesis
Chromatin/Epigenetic
JAK/STAT Signaling
Tyrosine Kinase/Adaptors
Stem Cells
Protein Tyrosine Kinase/RTK
Target
EGFR
HER2/ErbB2
FGFR
JAK1
PDGFR
EGFR, ERBB2
HER2 inhibitor
HER2
MOA
Inhibitor
protein tyrosine kinase inhibitor
Therapeutic Class
Anticancer Agents
Source data
